Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaFrance - Recruiting
Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
This study looks at how a medicine called Carglumic Acid helps people with rare conditions called Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) over a long time. It gathers information from patient records and talks to patients and their families.
Methylmalonic AcidemiaPropionic AcidemiaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)France - Ongoing, recruitingTherapeutic exploratory (Phase II)
OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
This study looks at how long immunotherapy works for people with advanced lung cancer and how it affects their bodies. We're testing different drug combinations to see which works best and for how long, to improve treatment plans.
Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.France - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaFrance - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia AFrance - Active not recruitingPHASE2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study is looking into a new medication called NS-229 for Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome. We want to see if NS-229 is safe and effective compared to a dummy treatment (placebo) when added to usual care.
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss SyndromeFrance - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)France - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)
This study looks at a special scan called a PET/CT with a tracer called 64Cu-ATSM. It aims to see if this scan can predict how well treatments, given before surgery for advanced bowel cancer (rectal cancer), will work. The goal is to find better ways to plan care.
Rectal adenocarcinomaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
This study is looking at a new medication called Tavapadon for people with Parkinson's disease. Researchers want to see if it's safe and how well it helps with symptoms over 58 weeks. It's a Phase 3 trial, meaning it's a big step towards potentially becoming a new treatment.
Parkinson's diseaseFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)
This study looks at new treatments for serious fungal infections called candidemia and invasive candidiasis. We are comparing a new medicine, ibrexafungerp, with an existing one, fluconazole, to see which works better and is safer after initial treatment with another antifungal.
Invasive Candidiasis/ CandidemiaFrance - RecruitingPHASE3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
This study looks at a new medicine called Vonicog Alfa for children with severe Von Willebrand Disease (VWD). It checks if this medicine can help prevent bleeding events in children who have previously used other VWD treatments.
Von Willebrand Disease (VWD)France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) once-weekly in participants with overweight or obesity
This study is looking at a new combination medicine, CagriSema, for adults who are overweight or have obesity. It wants to see if this weekly injection helps people lose weight and if it's safe to use. Researchers hope it can lead to meaningful weight loss.
ObesityFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination after topical application of IMIQUIMOD, in cirrhotic patients, who did not respond to the conventional vaccine regimen: a pilot study
This study looks at a new way to give the Hepatitis B vaccine to people with liver scarring (cirrhosis) who haven't responded to the usual vaccine. It checks if adding a cream called Imiquimod before the vaccine helps, and if this new method is safe.
France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
This study is testing different combinations of treatments for advanced lung cancer. It's looking to see how well these new drug combinations work and if they are safe. The aim is to find better ways to treat non-small cell lung cancer that has spread.
Metastatic non-small cell lung cancer (NSCLC)France - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
Hodgkin LymphomaFrance - Active not recruitingNA
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
This study is looking into a new way to help people with heart failure by stimulating a nerve called the vagal nerve. It involves a small implanted device and aims to improve heart health and quality of life.
Heart FailureCongestive Heart FailureFrance - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
Ovarian CancerFrance - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
This early-stage study is testing a new medicine, GSK3745417, for the first time in people with advanced cancers. Researchers want to see if it's safe and what doses are best, sometimes combined with other cancer drugs. Anyone aged 18 or over, male or female, with advanced cancer may be considered.
NeoplasmsFrance - Active not recruitingNA
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
This study looks at how well a product called SpaceOAR Vue helps men with prostate cancer. It aims to reduce gut problems when they have a type of radiation treatment called SBRT, by putting a special gel between the prostate and bowel.
Prostate CancerFrance - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryFrance - Enrolling by invitationPHASE3
Long-term Extension of GTX-102 in Angelman Syndrome
This study is looking into the long-term safety and effects of a treatment called GTX-102 for people with Angelman Syndrome. It's for those who have already been in an earlier study with this treatment.
Angelman SyndromeFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
This study is testing a new medicine, retifanlimab, alongside standard chemotherapy for anal canal cancer that has spread or come back. Researchers want to see if this new combination helps patients live longer without their cancer getting worse, compared to chemotherapy alone.
Squamous Carcinoma of the Anal CanalFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species
This study looks at a new medicine, olorofim, for serious fungal infections caused by Aspergillus. It compares olorofim to an existing treatment, AmBisome, to see which is safer and more effective for patients in the UK.
Invasive fungal infections due to Aspergillus spp.France - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL
This study is testing a new medicine called JNJ-75348780 for people with certain types of lymphoma and leukaemia. It's the very first time this medicine is being given to humans, to see if it's safe and how much to give.
Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)France - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerFrance - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaFrance - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskFrance - AuthorisedTherapeutic confirmatory (Phase III)
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
This study is looking at a new treatment called Kineret for children with a serious heart condition called myocarditis. It wants to see if Kineret helps their heart recover faster than a dummy treatment, by checking how well the heart pumps blood after 3 days.
PEDIATRIC ACUTE MYOCARDITISFrance - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A phase I of TG6050 in the treatment of patients with metastatic lung cancer
This study is looking into a new treatment called TG6050 for people with lung cancer that has spread. It's the first time this treatment is being given to humans, aiming to see if it's safe and what dose might work best.
Non-small cell lung cancer (NSCLC)France - AuthorisedTherapeutic exploratory (Phase II)
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
This study looks at a new way to treat high-risk skin cancer (melanoma) using a drug called Keytruda before surgery. Researchers want to see how well Keytruda shrinks the cancer and if it's safe for patients.
melanomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
This study is for people with a certain type of advanced lung cancer that has stopped responding to a previous treatment called osimertinib. It tests a new combination of two drugs, tepotinib and osimertinib, to see if it can shrink tumours.
Lung CancerFrance - Ongoing, recruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaFrance - AuthorisedTherapeutic confirmatory (Phase III)
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
This study looks at using strong steroid medicines to treat a type of stroke in children called focal cerebral arteriopathy (FCA). Researchers want to see if these medicines can reduce the inflammation in blood vessels and improve children's recovery.
Focal cerebral arteriopathy and childhood strokeFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall diseaseprovoked by infection.France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Evaluation of safety and pharmacokinetic parameters of the PTI5803 product
This study is testing a new medicine, PTI5803, for epilepsy. It's a very early stage trial to check if the medicine is safe and how it moves through the body in healthy adults. This helps scientists understand if it could be a good treatment for epilepsy in the future.
EpilepsyFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Amyotrophic Lateral Sclerosis (ALS)France - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO)
This study is testing two medicines, JEMPERLI and Zejula, together to see if they can help people with certain types of cancer. Doctors want to know how well this combination shrinks tumors and if it's safe to use. It's a next step in finding new cancer treatments.
DNA repair-deficient or platinum-sensitive solid tumorsFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
This study is looking at new ways to treat advanced stomach cancer in older patients. It compares two treatments, ramucirumab alone or with paclitaxel, to see which helps people live longer and have a better quality of life.
stomach cancer stage IV with metastasesFrance - Ongoing, recruitingTherapeutic use (Phase IV)
NIRAPK : Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer
This study looks at how a cancer drug called niraparib (Zejula) affects patients with ovarian cancer. Researchers want to understand why some patients experience side effects like changes in their blood or kidney problems, by studying how the body handles the drug.
Patients with high-grade serous epithelial ovarian, tubal or primary peritoneal cancersFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-linked chronic granulomatous disease
This study is testing a new gene therapy for X-linked Chronic Granulomatous Disease (X-CGD), a rare immune disorder. It uses a patient's own cells, modified in the lab, to help their immune system work better. Researchers are checking if it's safe and helps improve the body's ability to fight infections.
Treatment of X-linked Chronic Granulomatous DiseaseFrance - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaFrance - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2
This study is testing a new medicine, NMD670, for people with Charcot-Marie-Tooth disease types 1 and 2. It compares the medicine to a dummy pill to see if it helps people walk further and if it's safe over 21 days. Participants will be adults who can walk.
Charcot-Marie-Tooth Disease Type 1 and Type 2France - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DFrance